AstraZeneca signs license agreement with China’s CSPC worth up to $2bn
The agreement includes an upfront payment of $100m with the aim to strengthen the UK firm's cardiovascular portfolio.
October 09, 2024
Sour stock markets? No problem, ride it out. SARS? Been there, done that. Wars in the Middle East? Par for the course.
Registered users get 2 free articles in 30 days.
Subscribers have full unlimited access to FinanceAsia.
Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.
Questions?
See here for more information on licences and prices, or contact [email protected].